Andrew E. Clark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrew E. Clark has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
A. Brian Mochon
Banner Health
2 shared publications- David P. Nicolau
Center for Anti-Infective Research and Development, Hartford Hospital
2 shared publications Erik Munson
Department of Medical Laboratory Science, Marquette University
2 shared publications- Jeffrey A. SoRelle
Division of Allergy and Immunology, Department of Medicine and Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA
2 shared publications - Tomefa E. Asempa
Center for Anti-Infective Research and Development, Hartford Hospital
2 shared publications - Alagarraju Muthukumar
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam
We report an 8-fold increase in sulbactam-durlobactam minimum inhibitory concentrations in a carbapenem-resistant Acinetobacter baumannii isolate recovered after 14 days of sulbactam-durlobactam plus meropenem therapy for ventriculitis. Treatment-emergent mutations in the AdeFGH efflux system were identified, accompanied by a 166-fold increase in adeG expression. Efflux pump inhibition restored sulbactam-durlobactam susceptibility.
- 14 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessA Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam
We report an 8-fold increase in sulbactam-durlobactam minimum inhibitory concentrations in a carbapenem-resistant Acinetobacter baumannii isolate recovered after 14 days of sulbactam-durlobactam plus meropenem therapy for ventriculitis. Treatment-emergent mutations in the AdeFGH efflux system were identified, accompanied by a 166-fold increase in adeG expression. Efflux pump inhibition restored sulbactam-durlobactam susceptibility.
- Open Access
- 10 June 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical Validation of a Multiplex Real-Time PCR Assay for Rapid Identification of Mycobacterium tuberculosis complex, Nontuberculous Mycobacteria, and erm(41) Gene Carriage
The routine diagnosis of mycobacterial infections is complicated by the lack of FDA-approved diagnostic modalities and increasing requirements for sensitive methods to facilitate strain characterization and subspeciation. Although sequencing-based methods can be helpful, they are often restricted to reference laboratories due to expense and significant bioinformatics and regulatory requirements limiting routine use. Here, we developed and validated a novel multiplex TaqMan real‑time PCR assay for rapid identification of clinically important mycobacterial species (M. tuberculosis complex, M. avium complex, M. kansasii, and M. abscessus), and M. abscessus speciation through detection of the intact erythromycin ribosomal methylase (erm(41)) gene. The assay was performed on mycobacteria recovered from both solid and liquid culture media with a two-hour runtime. Identifications were compared to MALDI- and Sanger sequencing-derived identifications, demonstrating a 98% overall agreement, including 100% concordance for MTBC, M. abscessus, and M. kansasii, and 98% for MAC. It reliably detected intact erm(41) in 100% of M. abscessus isolates. This assay provides a rapid, scalable alternative for laboratories without routine access to sequencing.
- 10 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical Validation of a Multiplex Real-Time PCR Assay for Rapid Identification of Mycobacterium tuberculosis complex, Nontuberculous Mycobacteria, and erm(41) Gene Carriage
The routine diagnosis of mycobacterial infections is complicated by the lack of FDA-approved diagnostic modalities and increasing requirements for sensitive methods to facilitate strain characterization and subspeciation. Although sequencing-based methods can be helpful, they are often restricted to reference laboratories due to expense and significant bioinformatics and regulatory requirements limiting routine use. Here, we developed and validated a novel multiplex TaqMan real‑time PCR assay for rapid identification of clinically important mycobacterial species (M. tuberculosis complex, M. avium complex, M. kansasii, and M. abscessus), and M. abscessus speciation through detection of the intact erythromycin ribosomal methylase (erm(41)) gene. The assay was performed on mycobacteria recovered from both solid and liquid culture media with a two-hour runtime. Identifications were compared to MALDI- and Sanger sequencing-derived identifications, demonstrating a 98% overall agreement, including 100% concordance for MTBC, M. abscessus, and M. kansasii, and 98% for MAC. It reliably detected intact erm(41) in 100% of M. abscessus isolates. This assay provides a rapid, scalable alternative for laboratories without routine access to sequencing.
- Open Access
- 5 May 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (5) , e0328925
Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023–2025)
Acinetobacter baumannii most often causes pneumonia in critically ill patients. However, A. baumannii is also an important cause of a broader range of infections, including skin/wound and urinary tract infections. This study aims to evaluate the in vitro activity of sulbactam-durlobactam and comparator antibiotics, including meropenem and cefiderocol against A. baumannii-calcoaceticus complex isolates from non-respiratory and non-bloodstream sources. Samples included 285 A. baumannii-calcoaceticus complex isolates enriched for carbapenem resistance collected across 17 states in the United States (January 2023–May 2025). Antimicrobial susceptibility tests were conducted by manual broth microdilution and interpreted according to Clinical and Laboratory Standards Institute (CLSI) and Food and Drug Administration (FDA) (cefiderocol) standards. A. baumannii complex isolates were primarily cultured from skin/wound (58.6%), urinary tract (31.6%), and other sources (9.8%), including cerebrospinal and peritoneal fluid. Carbapenem resistance was observed in approximately 70% of isolates and more common among skin/wound cultures. Sulbactam-durlobactam was observed to be highly active (96.9% susceptible [S]; MIC 90 4 mg/L) and demonstrated greater activity than sulbactam (37.9% S; MIC 90 32 mg/L). Sulbactam-durlobactam also displayed high susceptibility rates across isolate sources, ranging from 96.4 (skin/wound) to 97.8% (urine). Cefiderocol demonstrated similar in vitro activity across culture sources and patient location, inhibiting >90 and >80% of isolates at CLSI and FDA susceptible breakpoints, respectively. Minocycline susceptibility was 69.1%, while tigecycline and eravacycline MICs 50/90 were 1/4 and 0.5/1 mg/L, respectively. The observed data are consistent with results from surveillance studies among respiratory and bloodstream isolates and show that sulbactam-durlobactam demonstrates potent in vitro activity against clinical A. baumannii complex isolates from a variety of culture sources. IMPORTANCE: Acinetobacter baumannii is a difficult-to-treat pathogen that often affects hospitalized patients and is known for a high level of multi-drug resistance. While commonly associated with pneumonia, it also causes infections in wounds, the urinary tract, and other parts of the body. This study shows that sulbactam-durlobactam is highly effective against A. baumannii from various infection sites. The results are important because they can inform clinicians on the susceptibility profiles of A. baumannii from a variety of infection sources, not just lung and bloodstream. As new antibiotics come onto the market, it is important to continuously assess resistance patterns to inform patient and system-wide health decisions.
- 5 May 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (5) , e0328925
Open AccessAntimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023–2025)
Acinetobacter baumannii most often causes pneumonia in critically ill patients. However, A. baumannii is also an important cause of a broader range of infections, including skin/wound and urinary tract infections. This study aims to evaluate the in vitro activity of sulbactam-durlobactam and comparator antibiotics, including meropenem and cefiderocol against A. baumannii-calcoaceticus complex isolates from non-respiratory and non-bloodstream sources. Samples included 285 A. baumannii-calcoaceticus complex isolates enriched for carbapenem resistance collected across 17 states in the United States (January 2023–May 2025). Antimicrobial susceptibility tests were conducted by manual broth microdilution and interpreted according to Clinical and Laboratory Standards Institute (CLSI) and Food and Drug Administration (FDA) (cefiderocol) standards. A. baumannii complex isolates were primarily cultured from skin/wound (58.6%), urinary tract (31.6%), and other sources (9.8%), including cerebrospinal and peritoneal fluid. Carbapenem resistance was observed in approximately 70% of isolates and more common among skin/wound cultures. Sulbactam-durlobactam was observed to be highly active (96.9% susceptible [S]; MIC 90 4 mg/L) and demonstrated greater activity than sulbactam (37.9% S; MIC 90 32 mg/L). Sulbactam-durlobactam also displayed high susceptibility rates across isolate sources, ranging from 96.4 (skin/wound) to 97.8% (urine). Cefiderocol demonstrated similar in vitro activity across culture sources and patient location, inhibiting >90 and >80% of isolates at CLSI and FDA susceptible breakpoints, respectively. Minocycline susceptibility was 69.1%, while tigecycline and eravacycline MICs 50/90 were 1/4 and 0.5/1 mg/L, respectively. The observed data are consistent with results from surveillance studies among respiratory and bloodstream isolates and show that sulbactam-durlobactam demonstrates potent in vitro activity against clinical A. baumannii complex isolates from a variety of culture sources. IMPORTANCE: Acinetobacter baumannii is a difficult-to-treat pathogen that often affects hospitalized patients and is known for a high level of multi-drug resistance. While commonly associated with pneumonia, it also causes infections in wounds, the urinary tract, and other parts of the body. This study shows that sulbactam-durlobactam is highly effective against A. baumannii from various infection sites. The results are important because they can inform clinicians on the susceptibility profiles of A. baumannii from a variety of infection sources, not just lung and bloodstream. As new antibiotics come onto the market, it is important to continuously assess resistance patterns to inform patient and system-wide health decisions.
- Open Access
- 4 November 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (6)
Bartonella -associated glomerulonephritis without endocarditis in a renal transplant recipient
Background: Bartonella henselae is a fastidious gram-negative rod that can cause systemic disease in immunocompromised patients. Infection may be complicated by glomerulonephritis, often in the setting of culture-negative infective endocarditis. The histologic pattern of Bartonella -associated glomerulonephritis is variable and often difficult to distinguish from non-infectious causes of glomerulonephritis by histopathology. Prompt, accurate diagnosis is further complicated by the poor sensitivity of routine culture methods for the detection of B. henselae , and serology or adjunctive molecular testing is typically required for microbiologic diagnosis. Case Summary: A middle-aged male renal transplant recipient was admitted to our hospital with fever, nausea, vomiting, diarrhea, and laboratory evidence of acute kidney injury. A thorough infectious disease work-up revealed markedly elevated B. henselae immunoglobulin G and immunoglobulin M titers and significant exposures to cats and fleas. A biopsy of the renal allograft revealed crescentic glomerulonephritis with immune complex deposition. No definitive evidence of infective endocarditis was found. The patient was started on renal replacement therapy and treated for disseminated bartonellosis with doxycycline and rifabutin. Conclusion: The diagnosis of Bartonella -associated glomerulonephritis in immunocompromised patients can be challenging from both the clinical and histopathologic perspectives. A high degree of clinical suspicion in patients with relevant risk factors is important for prompt diagnosis and treatment. Regardless of the presence or absence of typical signs and symptoms of cat scratch disease and/or infective endocarditis, Bartonella spp. should be included in the differential diagnosis of glomerulonephritis in solid-organ transplant recipients and other immunocompromised patients with cats or other relevant exposures.
- 4 November 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (6)
Open AccessBartonella -associated glomerulonephritis without endocarditis in a renal transplant recipient
Background: Bartonella henselae is a fastidious gram-negative rod that can cause systemic disease in immunocompromised patients. Infection may be complicated by glomerulonephritis, often in the setting of culture-negative infective endocarditis. The histologic pattern of Bartonella -associated glomerulonephritis is variable and often difficult to distinguish from non-infectious causes of glomerulonephritis by histopathology. Prompt, accurate diagnosis is further complicated by the poor sensitivity of routine culture methods for the detection of B. henselae , and serology or adjunctive molecular testing is typically required for microbiologic diagnosis. Case Summary: A middle-aged male renal transplant recipient was admitted to our hospital with fever, nausea, vomiting, diarrhea, and laboratory evidence of acute kidney injury. A thorough infectious disease work-up revealed markedly elevated B. henselae immunoglobulin G and immunoglobulin M titers and significant exposures to cats and fleas. A biopsy of the renal allograft revealed crescentic glomerulonephritis with immune complex deposition. No definitive evidence of infective endocarditis was found. The patient was started on renal replacement therapy and treated for disseminated bartonellosis with doxycycline and rifabutin. Conclusion: The diagnosis of Bartonella -associated glomerulonephritis in immunocompromised patients can be challenging from both the clinical and histopathologic perspectives. A high degree of clinical suspicion in patients with relevant risk factors is important for prompt diagnosis and treatment. Regardless of the presence or absence of typical signs and symptoms of cat scratch disease and/or infective endocarditis, Bartonella spp. should be included in the differential diagnosis of glomerulonephritis in solid-organ transplant recipients and other immunocompromised patients with cats or other relevant exposures.
- Open Access
- 4 November 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (6)
Reactive infectious mucocutaneous eruption: an increasingly encountered complication during periods of increased Mycoplasma pneumoniae transmission—a case report
Background: Mycoplasma pneumoniae is a common cause of community-acquired pneumonia among children and young adults. Surveillance within the United States has identified increased levels of M. pneumoniae -mediated respiratory disease following a multi-year period of minimal detection during the COVID-19 pandemic. A wide spectrum of extrapulmonary complications can be associated with M. pneumoniae infections, including dermatological disease. Reactive infectious mucocutaneous eruption (RIME) is a constellation of immune-mediated extrapulmonary manifestations causing ulceration of multiple mucous membranes that occurs in up to 25% M . pneumoniae cases. Case Summary: An adolescent patient presenting with acute hypoxic respiratory failure and an eight-day history of conjunctivitis and oral ulcers tested positive for M. pneumoniae from a nasopharyngeal specimen and was diagnosed with RIME. A retrospective review of increased M. pneumoniae test positivity and hospitalizations at our institution was undertaken, which mirrored national trends. Conclusion: As dedicated M. pneumoniae testing may not be available in all settings, clinicians should consider a diagnosis of RIME for patients presenting with similar para- or post-infectious mucositis, even in the absence of traditional respiratory symptoms. RIME incidence is expected to increase in the setting of a higher prevalence of M. pneumoniae disease. As RIME can be associated with significant morbidity including dehydration and weight loss as well as disease recurrence, proper management of patient symptomatology is essential.
- 4 November 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (6)
Open AccessReactive infectious mucocutaneous eruption: an increasingly encountered complication during periods of increased Mycoplasma pneumoniae transmission—a case report
Background: Mycoplasma pneumoniae is a common cause of community-acquired pneumonia among children and young adults. Surveillance within the United States has identified increased levels of M. pneumoniae -mediated respiratory disease following a multi-year period of minimal detection during the COVID-19 pandemic. A wide spectrum of extrapulmonary complications can be associated with M. pneumoniae infections, including dermatological disease. Reactive infectious mucocutaneous eruption (RIME) is a constellation of immune-mediated extrapulmonary manifestations causing ulceration of multiple mucous membranes that occurs in up to 25% M . pneumoniae cases. Case Summary: An adolescent patient presenting with acute hypoxic respiratory failure and an eight-day history of conjunctivitis and oral ulcers tested positive for M. pneumoniae from a nasopharyngeal specimen and was diagnosed with RIME. A retrospective review of increased M. pneumoniae test positivity and hospitalizations at our institution was undertaken, which mirrored national trends. Conclusion: As dedicated M. pneumoniae testing may not be available in all settings, clinicians should consider a diagnosis of RIME for patients presenting with similar para- or post-infectious mucositis, even in the absence of traditional respiratory symptoms. RIME incidence is expected to increase in the setting of a higher prevalence of M. pneumoniae disease. As RIME can be associated with significant morbidity including dehydration and weight loss as well as disease recurrence, proper management of patient symptomatology is essential.
- 1 April 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (4) , e0252724
Comparative phenotypic and genotypic antimicrobial susceptibility surveillance in Achromobacter spp. through whole genome sequencing
Treatment of Achromobacter infections remains challenging due to intrinsic and acquired resistance to commonly used antimicrobial agents and no established clinical breakpoints. We attempted accurate species-level identification and compared the presence of genotypic resistance markers to phenotypic susceptibility patterns in retrospectively collected clinical isolates of Achromobacter spp. Our study concludes that Achromobacter xylosoxidans is the most prevalent species. Commercial matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) systems cannot accurately identify all Achromobacter species due to the limited inclusion of spectra in the databases. Phenotypic antimicrobial susceptibility testing (AST) confirms resistance to the majority of antibiotics tested. Newer agents like delafloxacin, plazomicin, and omadacycline showed little or no activity, while minimum inhibitory concentrations were low for eravacycline. In general, the species other than A. xylosoxidans showed lower MIC 50 and MIC 90 , especially to carbapenems and β-lactamase inhibitor combinations like piperacillin-tazobactam, meropenem-vaborbactam, and imipenem-relebactam. Genotypic analysis confirmed that A. xylosoxidans carries a high number of resistance genes, including multidrug efflux pump AxyXY-OprZ, several class D (OXA-type), and the Class A ß-lactamase bla AXC , while Achromobacter mucicolens has the lowest number of resistance genes and no efflux pumps. This study concludes that there is significant genotypic and phenotypic diversity within the different species of Achromobacter, which are important for the identification of the species and for appropriate antimicrobial therapy. IMPORTANCE: Identification and susceptibility testing of Gram-negative non-fermenting bacteria belonging to the genus Achromobacter is difficult due to the lack of robust databases in commercial identification systems such as matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) and clinical breakpoints for antimicrobial agents. Most clinical laboratories interpret minimum inhibitory concentration data using the “non- Enterobacterales ” breakpoints included in the Clinical and Laboratory Standards Institute (CLSI) M100. These are breakpoints used for a group of organisms for which data is insufficient to provide species-specific interpretation. Our study provides phenotypic data regarding identification and susceptibility testing and correlates this with the genotypic characterization of 109 clinical isolates belonging to Achromobacter spp. This comprehensive study sheds light on the phenotypic and genotypic character of this bacteria, that is of increasing clinical relevance in hospital-acquired infections.
- 1 April 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (4) , e0252724
Comparative phenotypic and genotypic antimicrobial susceptibility surveillance in Achromobacter spp. through whole genome sequencing
Treatment of Achromobacter infections remains challenging due to intrinsic and acquired resistance to commonly used antimicrobial agents and no established clinical breakpoints. We attempted accurate species-level identification and compared the presence of genotypic resistance markers to phenotypic susceptibility patterns in retrospectively collected clinical isolates of Achromobacter spp. Our study concludes that Achromobacter xylosoxidans is the most prevalent species. Commercial matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) systems cannot accurately identify all Achromobacter species due to the limited inclusion of spectra in the databases. Phenotypic antimicrobial susceptibility testing (AST) confirms resistance to the majority of antibiotics tested. Newer agents like delafloxacin, plazomicin, and omadacycline showed little or no activity, while minimum inhibitory concentrations were low for eravacycline. In general, the species other than A. xylosoxidans showed lower MIC 50 and MIC 90 , especially to carbapenems and β-lactamase inhibitor combinations like piperacillin-tazobactam, meropenem-vaborbactam, and imipenem-relebactam. Genotypic analysis confirmed that A. xylosoxidans carries a high number of resistance genes, including multidrug efflux pump AxyXY-OprZ, several class D (OXA-type), and the Class A ß-lactamase bla AXC , while Achromobacter mucicolens has the lowest number of resistance genes and no efflux pumps. This study concludes that there is significant genotypic and phenotypic diversity within the different species of Achromobacter, which are important for the identification of the species and for appropriate antimicrobial therapy. IMPORTANCE: Identification and susceptibility testing of Gram-negative non-fermenting bacteria belonging to the genus Achromobacter is difficult due to the lack of robust databases in commercial identification systems such as matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) and clinical breakpoints for antimicrobial agents. Most clinical laboratories interpret minimum inhibitory concentration data using the “non- Enterobacterales ” breakpoints included in the Clinical and Laboratory Standards Institute (CLSI) M100. These are breakpoints used for a group of organisms for which data is insufficient to provide species-specific interpretation. Our study provides phenotypic data regarding identification and susceptibility testing and correlates this with the genotypic characterization of 109 clinical isolates belonging to Achromobacter spp. This comprehensive study sheds light on the phenotypic and genotypic character of this bacteria, that is of increasing clinical relevance in hospital-acquired infections.
- 20 January 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (3) , 106733
Antimicrobial Activity of Tebipenem and Comparators against Enterobacterales from diverse Outpatient Centers and Nursing Homes in the United States
- 20 January 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (3) , 106733
Antimicrobial Activity of Tebipenem and Comparators against Enterobacterales from diverse Outpatient Centers and Nursing Homes in the United States
- Open Access
- 25 May 2022
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 68 (8) , 1042-1052
Multiplex Fragment Analysis for Flexible Detection of All SARS-CoV-2 Variants of Concern
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge, and effective tracking requires rapid return of results. Surveillance of variants is typically performed by whole genome sequencing (WGS), which can be financially prohibitive and requires specialized equipment and bioinformatic expertise. Genotyping approaches are rapid methods for monitoring SARS-CoV-2 variants but require continuous adaptation. Fragment analysis may represent an approach for improved SARS-CoV-2 variant detection. Methods: A multiplex fragment analysis approach (CoVarScan) was validated using PCR targeting variants by size and fluorescent color. Eight SARS-CoV-2 mutational hot spots in variants of concern (VOCs) were targeted. Three primer pairs (recurrently deleted region [RDR] 1, RDR2, and RDR3–4) flank RDRs in the S-gene. Three allele-specific primers target recurrent spike receptor binding domain mutants. Lastly, 2 primer pairs target recurrent deletions or insertions in ORF1A and ORF8. Fragments were resolved and analyzed by capillary electrophoresis (ABI 3730XL), and mutational signatures were compared to WGS results. Results: We validated CoVarScan using 3544 clinical respiratory specimens. The assay exhibited 96% sensitivity and 99% specificity compared to WGS. The limit of detection for the core targets (RDR1, RDR2, and ORF1A) was 5 copies/reaction. Variants were identified in 95% of samples with cycle threshold (CT) <30 and 75% of samples with a CT 34 to 35. Assay design was frozen April 2021, but all subsequent VOCs have been detected including Delta (n = 2820), Mu, (n = 6), Lambda (n = 6), and Omicron (n = 309). Genotyping results are available in as little as 4 h. Conclusions: Multiplex fragment analysis is adaptable and rapid and has similar accuracy to WGS to classify SARS-CoV-2 variants.
- 25 May 2022
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 68 (8) , 1042-1052
Open AccessMultiplex Fragment Analysis for Flexible Detection of All SARS-CoV-2 Variants of Concern
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge, and effective tracking requires rapid return of results. Surveillance of variants is typically performed by whole genome sequencing (WGS), which can be financially prohibitive and requires specialized equipment and bioinformatic expertise. Genotyping approaches are rapid methods for monitoring SARS-CoV-2 variants but require continuous adaptation. Fragment analysis may represent an approach for improved SARS-CoV-2 variant detection. Methods: A multiplex fragment analysis approach (CoVarScan) was validated using PCR targeting variants by size and fluorescent color. Eight SARS-CoV-2 mutational hot spots in variants of concern (VOCs) were targeted. Three primer pairs (recurrently deleted region [RDR] 1, RDR2, and RDR3–4) flank RDRs in the S-gene. Three allele-specific primers target recurrent spike receptor binding domain mutants. Lastly, 2 primer pairs target recurrent deletions or insertions in ORF1A and ORF8. Fragments were resolved and analyzed by capillary electrophoresis (ABI 3730XL), and mutational signatures were compared to WGS results. Results: We validated CoVarScan using 3544 clinical respiratory specimens. The assay exhibited 96% sensitivity and 99% specificity compared to WGS. The limit of detection for the core targets (RDR1, RDR2, and ORF1A) was 5 copies/reaction. Variants were identified in 95% of samples with cycle threshold (CT) <30 and 75% of samples with a CT 34 to 35. Assay design was frozen April 2021, but all subsequent VOCs have been detected including Delta (n = 2820), Mu, (n = 6), Lambda (n = 6), and Omicron (n = 309). Genotyping results are available in as little as 4 h. Conclusions: Multiplex fragment analysis is adaptable and rapid and has similar accuracy to WGS to classify SARS-CoV-2 variants.
- Open Access
- 4 December 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (Supplement) , S701
1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
Cystic fibrosis (CF) patients are often colonized with Pseudomonas aeruginosa (PSA). During treatment, PSA can develop subpopulations exhibiting variable in vitro antimicrobial susceptibility patterns. Heteroresistance may underlie the reported discordant in vitro results and clinical responses to various antimicrobials. Here, we sought to examine the presence and nature of PSA heteroresistance to ceftolozane-tazobactam (C-T) in isolates originating from CF pulmonary exacerbations. Respiratory cultures from 26 adult CF patients were collected. From each sample, 5-10 PSA colonies were selected. Susceptibility testing was conducted via E-test for C-T, ceftazidime-avibactam (CZA), and imipenem-relebactam (I-R). Polyclonal-heteroresistance (PHR) was defined as the presence of different susceptibility profiles among the colonies that originated from a single patient specimen. Population analysis profile (PAPs) were performed to assess the presence of monoclonal-heteroresistance (MHR), defined as ≥ 4 fold change in the C-T MIC from a single colony over 24-48 hours. 246 PSA isolates from 26 adult CF patients were included. The C-T MIC50 and MIC90 were 1/4 and ≥ 256/4 µg/mL, respectively (Figure 1). Sixteen of the 26 patients (62%) demonstrated ≥ 2 fold change in C-T MIC between isolates from the same culture. Of these 16 isolates, the fold change in C-T MIC was >2 fold for 7 isolates (27%) and resulted in a susceptibility interpretation change in 6 of the isolates (23%). Of the 32 isolates that underwent PAP testing, 7 grew on MH plates at 2-fold the C-T MIC concentration. One isolate, PSA 1311, demonstrated growth on PAPs up to 4 fold the MIC (16/4 µg/mL) (Figure 2). Figure 1. Ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam MIC distributions against PSA isolates from 26 adult CF patients Figure 2. Monoclonal heteroresistance to C-T (PSA 1311 [C-T MIC 1/4 µg/mL] PAPs at 2, 4, 6, and 8-fold the C-T MIC). Susceptibilities to C-T and CZA were similar across our CF PSA isolates. Comparatively, I-R retained better in vitro potency. C-T PHR exists among PSA isolates in the majority of our CF patients. Approximately 25% of these PHR isolates resulted in susceptibility interpretation changes supporting concerns surrounding the utility of traditional susceptibility testing methodology for CF isolates. These data suggest MHR also exists, albeit rare in this small subset. Additional data are needed to better understand these results in clinical context. David E. Greenberg, MD, Shionogi (Grant/Research Support)Solenic Medical (Shareholder)
- 4 December 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (Supplement) , S701
Open Access1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
Cystic fibrosis (CF) patients are often colonized with Pseudomonas aeruginosa (PSA). During treatment, PSA can develop subpopulations exhibiting variable in vitro antimicrobial susceptibility patterns. Heteroresistance may underlie the reported discordant in vitro results and clinical responses to various antimicrobials. Here, we sought to examine the presence and nature of PSA heteroresistance to ceftolozane-tazobactam (C-T) in isolates originating from CF pulmonary exacerbations. Respiratory cultures from 26 adult CF patients were collected. From each sample, 5-10 PSA colonies were selected. Susceptibility testing was conducted via E-test for C-T, ceftazidime-avibactam (CZA), and imipenem-relebactam (I-R). Polyclonal-heteroresistance (PHR) was defined as the presence of different susceptibility profiles among the colonies that originated from a single patient specimen. Population analysis profile (PAPs) were performed to assess the presence of monoclonal-heteroresistance (MHR), defined as ≥ 4 fold change in the C-T MIC from a single colony over 24-48 hours. 246 PSA isolates from 26 adult CF patients were included. The C-T MIC50 and MIC90 were 1/4 and ≥ 256/4 µg/mL, respectively (Figure 1). Sixteen of the 26 patients (62%) demonstrated ≥ 2 fold change in C-T MIC between isolates from the same culture. Of these 16 isolates, the fold change in C-T MIC was >2 fold for 7 isolates (27%) and resulted in a susceptibility interpretation change in 6 of the isolates (23%). Of the 32 isolates that underwent PAP testing, 7 grew on MH plates at 2-fold the C-T MIC concentration. One isolate, PSA 1311, demonstrated growth on PAPs up to 4 fold the MIC (16/4 µg/mL) (Figure 2). Figure 1. Ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam MIC distributions against PSA isolates from 26 adult CF patients Figure 2. Monoclonal heteroresistance to C-T (PSA 1311 [C-T MIC 1/4 µg/mL] PAPs at 2, 4, 6, and 8-fold the C-T MIC). Susceptibilities to C-T and CZA were similar across our CF PSA isolates. Comparatively, I-R retained better in vitro potency. C-T PHR exists among PSA isolates in the majority of our CF patients. Approximately 25% of these PHR isolates resulted in susceptibility interpretation changes supporting concerns surrounding the utility of traditional susceptibility testing methodology for CF isolates. These data suggest MHR also exists, albeit rare in this small subset. Additional data are needed to better understand these results in clinical context. David E. Greenberg, MD, Shionogi (Grant/Research Support)Solenic Medical (Shareholder)
- Open Access
- 1 February 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (2) , 305-311
Multicenter Evaluation of MRSASelectII Chromogenic Agar for Identification of Methicillin-Resistant Staphylococcus aureus from Wound and Nasal Specimens
Hospitals strive to reduce methicillin-resistantStaphylococcus aureus(MRSA) prevalence via active surveillance of inpatient populations. Rapid and inexpensive screening methods are utilized when molecular methods are not operationally feasible. In this multisite clinical trial, the utility of Bio-Rad's MRSASelectII was evaluated for MRSA identification from remnant nares and wound swabs. The prevalence of MRSA was 11.1% (n= 1,384) from nares samples and 18.1% (n= 842) from wound samples. MRSASelectII had an overall concordance of 95.4% (confidence interval [CI] = 94.5% to 96.2%) compared to a broth-enriched reference standard. Comparisons between results, stratified by examination times, exhibited a nonsignificant trend toward increased positivity at prolonged incubation times. Cefoxitin screening of colonies directly from MRSASelectII was 96.7% (95.8% to 97.3%) concordant compared to testing of colonies following broth enrichment. A comparison of MRSASelectand MRSASelectII revealed no statistical differences; however, the latter exhibited earlier positivity, greater selectivity, and more intense indicator staining, which resulted in facilitated differentiation of positive results. MRSASelectII agar is a simple, rapid, and robust method to routinely screen patients for MRSA colonization without the need for additional testing.
- 1 February 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (2) , 305-311
Open AccessMulticenter Evaluation of MRSASelectII Chromogenic Agar for Identification of Methicillin-Resistant Staphylococcus aureus from Wound and Nasal Specimens
Hospitals strive to reduce methicillin-resistantStaphylococcus aureus(MRSA) prevalence via active surveillance of inpatient populations. Rapid and inexpensive screening methods are utilized when molecular methods are not operationally feasible. In this multisite clinical trial, the utility of Bio-Rad's MRSASelectII was evaluated for MRSA identification from remnant nares and wound swabs. The prevalence of MRSA was 11.1% (n= 1,384) from nares samples and 18.1% (n= 842) from wound samples. MRSASelectII had an overall concordance of 95.4% (confidence interval [CI] = 94.5% to 96.2%) compared to a broth-enriched reference standard. Comparisons between results, stratified by examination times, exhibited a nonsignificant trend toward increased positivity at prolonged incubation times. Cefoxitin screening of colonies directly from MRSASelectII was 96.7% (95.8% to 97.3%) concordant compared to testing of colonies following broth enrichment. A comparison of MRSASelectand MRSASelectII revealed no statistical differences; however, the latter exhibited earlier positivity, greater selectivity, and more intense indicator staining, which resulted in facilitated differentiation of positive results. MRSASelectII agar is a simple, rapid, and robust method to routinely screen patients for MRSA colonization without the need for additional testing.